Literature DB >> 29209646

Re-investigating PLK1 inhibitors as antimitotic agents.

Quentin Delacour1,2, Olivier Gavet3,1,2.   

Abstract

Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells.

Entities:  

Keywords:  G2 phase; Polo-like kinase 1; antimitotic; cancer; kinase inhibitor

Year:  2017        PMID： 29209646      PMCID： PMC5706940          DOI： 10.1080/23723556.2017.1356430

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  9 in total

1.  Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Authors:  Y Wang; J Li; R N Booher; A Kraker; T Lawrence; W R Leopold; Y Sun
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

2.  PLK1 Activation in Late G2 Sets Up Commitment to Mitosis.

Authors:  Lilia Gheghiani; Damarys Loew; Bérangère Lombard; Jörg Mansfeld; Olivier Gavet
Journal:  Cell Rep       Date:  2017-06-06       Impact factor: 9.423

Review 3.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

4.  Cdk1 Phosphorylates SPAT-1/Bora to Promote Plk1 Activation in C. elegans and Human Cells.

Authors:  Yann Thomas; Luca Cirillo; Costanza Panbianco; Lisa Martino; Nicolas Tavernier; Françoise Schwager; Lucie Van Hove; Nicolas Joly; Anna Santamaria; Lionel Pintard; Monica Gotta
Journal:  Cell Rep       Date:  2016-04-07       Impact factor: 9.423

5.  High mitotic activity of Polo-like kinase 1 is required for chromosome segregation and genomic integrity in human epithelial cells.

Authors:  Robert F Lera; Mark E Burkard
Journal:  J Biol Chem       Date:  2012-10-27       Impact factor: 5.157

6.  Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells.

Authors:  Mark E Burkard; Catherine L Randall; Stéphane Larochelle; Chao Zhang; Kevan M Shokat; Robert P Fisher; Prasad V Jallepalli
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-06       Impact factor: 11.205

7.  Mitotic entry: Non-genetic heterogeneity exposes the requirement for Plk1.

Authors:  Claire F Aspinall; Daniella Zheleva; Anthony Tighe; Stephen S Taylor
Journal:  Oncotarget       Date:  2015-11-03

Review 8.  PLK1, A Potential Target for Cancer Therapy.

Authors:  Zhixian Liu; Qingrong Sun; Xiaosheng Wang
Journal:  Transl Oncol       Date:  2016-11-24       Impact factor: 4.243

Review 9.  The decision to enter mitosis: feedback and redundancy in the mitotic entry network.

Authors:  Arne Lindqvist; Verónica Rodríguez-Bravo; René H Medema
Journal:  J Cell Biol       Date:  2009-04-13       Impact factor: 10.539
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.